Activator of peroxisome proliferator-activated receptor δ

A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I):

• or a salt thereof,
• wherein A is O, S or NR7 in which R7 is hydrogen or C1-8 alkyl;
• B1 is CW or N in which W is hydrogen or a bond;
• B2 is O, S or NR8 in which R8 is hydrogen or C1-8 alkyl;
• each of X1 and X2 is O, S, NH, NHC(═O), C(═O), C(═N—OR9), CH(OR10), —CH═CH—, C═C or a bond in which each of R9 and R10 is hydrogen or C1-8 alkyl;
• Y is a C1-8 alkylene chain, which is optionally substituted with C1-8 alkyl or C1-8 alkyl substituted with 1-3 halogens;
• Z is NH, O or S
• R1 is aryl, which is optionally substituted with a group or atom selected from the group consisting of 1-8 alkyl, C1-8 alkoxy, C1-8 alkyl substituted with 1-3 halogens, hydroxyl, nitro, amino, phenyl, pyridyl and halogen, or a heterocyclic group having five to eight membered ring comprising one to three hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur and the other atoms consisting of carbon, wherein a benzene ring is optionally condensed with the heterocyclic ring;
• R2 is C2-8 alkyl, C1-8 alkyl substituted with 1-3 halogens, C3-7 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, C1-4 alkyl substituted with aryl, which is optionally substituted with a group or atom selected from the group consisting of C1-8 alkyl, C1-8 alkoxy, C1-8 alkyl substituted with 1-3 halogens, hydroxyl, nitro, amino, phenyl, pyridyl and halogen, or C1-4 alkyl substituted with a heterocyclic group having a five to eight membered ring, comprising one to three hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, and the other atoms are carbon;
• R3 is halogen, trifluoromethyl, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;
• each of R4 and R5 is independently hydrogen, C1-8 alkyl or C1-8 alkyl substituted with 1-3 halogens;
• and
• R6 is hydrogen, C1-8 alkyl substituted with amino, C1-8 alkyl or alkali metal;
• provided that each of Z and R3 is attached to the benzene ring, and X2 is not attached to the benzene ring;
• and
• a pharmaceutically acceptable carrier.